Itk Inhibitors
2 drugsAbout Itk
Interleukin-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase crucial for T-cell receptor signaling. As a Tec family kinase, Itk regulates T-cell development, activation, and differentiation through downstream signaling pathways.
While no genetic evidence directly links Itk to specific diseases, its involvement in T-cell function makes it a relevant therapeutic target. Modulating Itk activity may offer therapeutic benefits in immune-related disorders.
Itk is targeted by 2 FDA-approved small molecule drugs, including VOTRIENT (pazopanib hydrochloride). These drugs, marketed by Novartis and NOVUGEN, are primarily used in oncology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Soft-tissue Sarcoma with only 1 trials.
- phase2 represents biological uncertainty with 40% completion.
Top Itk Drugs
The Itk drug market is concentrated with Novartis and NOVUGEN holding approved drugs.
High market concentration suggests significant barriers to entry for new competitors.
Itk Drug Modality Landscape
Modalities
Routes of Administration
Itk is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Itk Clinical Trials 153 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 49 | 31 | 12 | 6 | 72% |
| Phase 2 | 91 | 59 | 25 | 7 | 70% |
| Phase 3 | 10 | 7 | 0 | 3 | 100% |
| Phase 4 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Itk Drug Approval Timeline (2009 - 2023)
The first Itk-targeting drug was approved in 2009, with the most recent approval in 2023.
The 15-year span between approvals indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 47 clinical trials targeting Itk.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities